Praxis Precision (PRAX) Medicines announced that, following a comprehensive Type B meeting and recent meeting minutes and written advice on the protocol and SAP, it has reached alignment with the FDA on several aspects of the relutrigine program in SCN2A and SCN8A developmental and epileptic encephalopathies, including the use of the ongoing EMBOLD study to serve as the basis of substantial evidence of effectiveness for the NDA submission. The FDA agreed that Praxis’ proposed interim analysis, if positive, may serve as the basis of the NDA submission in early 2026. The interim analysis is planned to be conducted in the fourth quarter of 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines Advances Elsunersen Trial for Pediatric Epileptic Encephalopathy
- Praxis Precision Medicines Advances Phase 3 Trial for DEE Treatment
- Praxis Precision Medicines Advances Phase 3 Study for Essential Tremor Treatment
- Praxis Precision Medicines’ PRAX-222 Trial: A Potential Game-Changer for Pediatric Epilepsy
- Praxis Precision Medicines’ PRAX-628 Study: A Potential Game-Changer for Focal Seizures